UM  > 健康科學學院
Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole
Shim J.S.1; Li R.-J.1; Bumpus N.N.1; Head S.A.1; Pasunooti K.K.1; Yang E.J.3; Lv J.3; Shi W.1,2; Liu J.O.1
2016-06-01
Source PublicationClinical Cancer Research
ISSN15573265 10780432
Volume22Issue:11Pages:2709-2720
Abstract

Purpose: Itraconazole is a triazole antifungal drug that has recently been found to inhibit angiogenesis. Itraconazole is a relatively well-tolerated drug but shows hepatotoxicity in a small subset of patients. Itraconazole contains three chiral centers and the commercial itraconazole is composed of four cis-stereoisomers (named IT-A, IT-B, IT-C, and IT-D). We sought to determine whether the stereoisomers of itraconazole might differ in their antiangiogenic activity and hepatotoxicity. Experimental Design: We assessed in vitro antiangiogenic activity of itraconazole and each stereoisomer using human umbilical vein endothelial cell (HUVEC) proliferation and tube formation assays. We also determined their hepatotoxicity using primary human hepatocytes in vitro and a mouse model in vivo. Mouse Matrigel plug and tumor xenograft models were used to evaluate in vivo antiangiogenic and antitumor activities of the stereoisomers. Results: Of the four stereoisomers contained in commercial itraconazole, we found that IT-A (2S,4R,20R) and IT-C (2S,4R,20S) were more potent for inhibition of angiogenesis than IT-B (2R,4S,20R) and IT-D (2R,4S,20S). Interestingly, IT-A and IT-B were more hepatotoxic than IT-C and IT-D. In mouse models, IT-C showed more potent antiangiogenic/antitumor activity with lower hepatotoxicity compared with itraconazole and IT-A. Conclusions: These results demonstrate the segregation of influence of stereochemistry at different positions of itraconazole on its antiangiogenic activity and hepatotoxicity, with the 2 and 4 positions affecting the former and the 20 position affecting the latter. They also suggest that IT-C may be superior to the racemic mixture of itraconazole as an anticancer drug candidate due to its lower hepatotoxicity and improved antiangiogenic activity.

DOI10.1158/1078-0432.CCR-15-1888
URLView the original
Indexed BySCIE
Language英语
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000378338200016
Fulltext Access
Citation statistics
Cited Times [WOS]:7   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorLiu J.O.
Affiliation1.The Johns Hopkins School of Medicine
2.University of Arkansas - Fayetteville
3.Universidade de Macau
Recommended Citation
GB/T 7714
Shim J.S.,Li R.-J.,Bumpus N.N.,et al. Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole[J]. Clinical Cancer Research,2016,22(11):2709-2720.
APA Shim J.S..,Li R.-J..,Bumpus N.N..,Head S.A..,Pasunooti K.K..,...&Liu J.O..(2016).Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole.Clinical Cancer Research,22(11),2709-2720.
MLA Shim J.S.,et al."Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole".Clinical Cancer Research 22.11(2016):2709-2720.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Shim J.S.]'s Articles
[Li R.-J.]'s Articles
[Bumpus N.N.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Shim J.S.]'s Articles
[Li R.-J.]'s Articles
[Bumpus N.N.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Shim J.S.]'s Articles
[Li R.-J.]'s Articles
[Bumpus N.N.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.